Soluble interleukin 6 receptor in biological fluids from human origin. 1994

J T Frieling, and R W Sauerwein, and J Wijdenes, and T Hendriks, and C J van der Linden
Department of Surgery, University Hospital, Nijmegen, The Netherlands.

OBJECTIVE measurement of baseline soluble interleukin 6 receptor (sIL-6R) and interleukin 6 (IL-6) levels in biological fluids in non-pathological conditions. METHODS Blood and urine were obtained from healthy volunteers. Cerebrospinal fluid (CSF) and synovial fluid (SF) were obtained from patients during spinal puncture and athroscopy, respectively. Only CSF and SF of patients with proven non-pathological conditions were used in this study. Both sIL-6R and IL-6 were measured using ELISAs. It was shown that neither did sIL-6R interfere with the IL-6 ELISA nor did IL-6 interfere in the sIL-6R ELISA. Moreover, addition of recombinant sIL-6R to the IL-6 bio-assay (B9) did not influence IL-6 recovery. RESULTS using our sIL-6R ELISA we found baseline levels for sIL-6R in serum of 76.6 +/- 19.3 ng/ml in serum and 3.7 +/- 1.3 ng/ml in urine. In non-pathological conditions sIL-6R concentrations in CSF are 1.6 +/- 0.4 ng/ml, and in SF 11.6 +/- 3.3 ng/ml, while IL-6 concentrations are below detectable ranges in these fluids. CONCLUSIONS sIL-6R levels are detectable in serum, urine, CSF and SF during non-pathological conditions. sIL-6R levels in serum outrange levels in CSF, urine and SF and large interindividual differences in baseline concentrations for sIL-6R exist.

UI MeSH Term Description Entries
D012016 Reference Values The range or frequency distribution of a measurement in a population (of organisms, organs or things) that has not been selected for the presence of disease or abnormality. Normal Range,Normal Values,Reference Ranges,Normal Ranges,Normal Value,Range, Normal,Range, Reference,Ranges, Normal,Ranges, Reference,Reference Range,Reference Value,Value, Normal,Value, Reference,Values, Normal,Values, Reference
D001826 Body Fluids Liquid components of living organisms. Body Fluid,Fluid, Body,Fluids, Body
D004797 Enzyme-Linked Immunosorbent Assay An immunoassay utilizing an antibody labeled with an enzyme marker such as horseradish peroxidase. While either the enzyme or the antibody is bound to an immunosorbent substrate, they both retain their biologic activity; the change in enzyme activity as a result of the enzyme-antibody-antigen reaction is proportional to the concentration of the antigen and can be measured spectrophotometrically or with the naked eye. Many variations of the method have been developed. ELISA,Assay, Enzyme-Linked Immunosorbent,Assays, Enzyme-Linked Immunosorbent,Enzyme Linked Immunosorbent Assay,Enzyme-Linked Immunosorbent Assays,Immunosorbent Assay, Enzyme-Linked,Immunosorbent Assays, Enzyme-Linked
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D001681 Biological Assay A method of measuring the effects of a biologically active substance using an intermediate in vivo or in vitro tissue or cell model under controlled conditions. It includes virulence studies in animal fetuses in utero, mouse convulsion bioassay of insulin, quantitation of tumor-initiator systems in mouse skin, calculation of potentiating effects of a hormonal factor in an isolated strip of contracting stomach muscle, etc. Bioassay,Assay, Biological,Assays, Biological,Biologic Assay,Biologic Assays,Assay, Biologic,Assays, Biologic,Bioassays,Biological Assays
D012995 Solubility The ability of a substance to be dissolved, i.e. to form a solution with another substance. (From McGraw-Hill Dictionary of Scientific and Technical Terms, 6th ed) Solubilities
D013582 Synovial Fluid The clear, viscous fluid secreted by the SYNOVIAL MEMBRANE. It contains mucin, albumin, fat, and mineral salts and serves to lubricate joints. Synovia,Fluid, Synovial,Fluids, Synovial,Synovial Fluids
D015850 Interleukin-6 A cytokine that stimulates the growth and differentiation of B-LYMPHOCYTES and is also a growth factor for HYBRIDOMAS and plasmacytomas. It is produced by many different cells including T-LYMPHOCYTES; MONOCYTES; and FIBROBLASTS. Hepatocyte-Stimulating Factor,Hybridoma Growth Factor,IL-6,MGI-2,Myeloid Differentiation-Inducing Protein,Plasmacytoma Growth Factor,B Cell Stimulatory Factor-2,B-Cell Differentiation Factor,B-Cell Differentiation Factor-2,B-Cell Stimulatory Factor 2,B-Cell Stimulatory Factor-2,BSF-2,Differentiation Factor, B-Cell,Differentiation Factor-2, B-Cell,IFN-beta 2,IL6,Interferon beta-2,B Cell Differentiation Factor,B Cell Differentiation Factor 2,B Cell Stimulatory Factor 2,Differentiation Factor 2, B Cell,Differentiation Factor, B Cell,Differentiation-Inducing Protein, Myeloid,Growth Factor, Hybridoma,Growth Factor, Plasmacytoma,Hepatocyte Stimulating Factor,Interferon beta 2,Interleukin 6,Myeloid Differentiation Inducing Protein,beta-2, Interferon
D018123 Receptors, Interleukin Cell surface proteins that bind interleukins and trigger intracellular changes influencing the behavior of cells. Interleukin Receptors,Interleukin Receptor,Receptors, Interleukins,Interleukins Receptors,Receptor, Interleukin
D019947 Receptors, Interleukin-6 Cell surface receptors that are specific for INTERLEUKIN-6. They are present on T-LYMPHOCYTES, mitogen-activated B-LYMPHOCYTES, and peripheral MONOCYTES. The receptors are heterodimers of the INTERLEUKIN-6 RECEPTOR ALPHA SUBUNIT and the CYTOKINE RECEPTOR GP130. IL-6 Receptors,Interleukin-6 Receptor,Interleukin-6 Receptors,Receptors, IL-6,IL-6 Receptor,IL6 Receptor,IL6 Receptors,Interleukin 6 Receptor,IL 6 Receptor,IL 6 Receptors,Interleukin 6 Receptors,Receptor, IL-6,Receptor, IL6,Receptor, Interleukin 6,Receptor, Interleukin-6,Receptors, IL 6,Receptors, IL6,Receptors, Interleukin 6

Related Publications

J T Frieling, and R W Sauerwein, and J Wijdenes, and T Hendriks, and C J van der Linden
May 2003, Clinical and experimental medicine,
J T Frieling, and R W Sauerwein, and J Wijdenes, and T Hendriks, and C J van der Linden
November 1990, Cytokine,
J T Frieling, and R W Sauerwein, and J Wijdenes, and T Hendriks, and C J van der Linden
November 1999, Nihon rinsho. Japanese journal of clinical medicine,
J T Frieling, and R W Sauerwein, and J Wijdenes, and T Hendriks, and C J van der Linden
January 1997, Hematology (Amsterdam, Netherlands),
J T Frieling, and R W Sauerwein, and J Wijdenes, and T Hendriks, and C J van der Linden
September 2002, Cytokine,
J T Frieling, and R W Sauerwein, and J Wijdenes, and T Hendriks, and C J van der Linden
January 1998, Immunological investigations,
J T Frieling, and R W Sauerwein, and J Wijdenes, and T Hendriks, and C J van der Linden
October 1996, Biochemical and biophysical research communications,
J T Frieling, and R W Sauerwein, and J Wijdenes, and T Hendriks, and C J van der Linden
July 1995, Annals of the New York Academy of Sciences,
J T Frieling, and R W Sauerwein, and J Wijdenes, and T Hendriks, and C J van der Linden
August 2005, Nihon rinsho. Japanese journal of clinical medicine,
J T Frieling, and R W Sauerwein, and J Wijdenes, and T Hendriks, and C J van der Linden
December 2006, International journal of cancer,
Copied contents to your clipboard!